

Nuformix hoping to "initiate discussions with major pharma" in 2023



DIGITAL ASSET DIRECT BY NUFORMIX PLC

London, UK | December 20, 2022 08:00 AM Eastern Standard Time



Nuformix PLC (LSE:NFX) executive director Dr Dan Gooding speaks to Proactive shortly after releasing an update on the company's NXP004 programme, aimed at developing novel forms of AstraZeneca's Olaparib (Lynparza) cancer drug. Gooding reveals what investors can expect from Nuformix in 2023, saying that his aspiration is for data from the NXP002 programme to be supportive of the company "initiating discussions with major pharma."

Contact Details

Proactive

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Tags

HEALTH

PHARMA & BIOTECH

CANCER